Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

Julie Hejl; Klaus Theede; Brian Møllgren; Kirsten Vikkelsø Madsen; Ashraf Heidari; Anna á Steig; Mogens Fenger

doi:https://doi.org/10.1016/j.plabm.2017.11.002

Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

Julie Hejl, Klaus Theede, Brian Møllgren, Kirsten Vikkelsø Madsen, Ashraf Heidari, Anna á Steig, Mogens Fenger

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

Objectives Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1–2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration. Design and methods Fifty-five stool samples were analyzed by the IBDoc ^® Calprotectin Home Testing kit and the BÜHLMANN fCAL ^® turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated. Results We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL ^® turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3–5.5% (BÜHLMANN fCAL ^® turbo) and in the range of 4.8–26.6% (IBDoc ^®). Conclusions This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients.

Translated title of the contribution	Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis
Original language	English
Journal	Practical Laboratory Medicine
Volume	10
Pages (from-to)	10-14
Number of pages	5
ISSN	2352-5517
DOIs	https://doi.org/10.1016/j.plabm.2017.11.002
Publication status	Published - Mar 2018

Keywords

clinical assessment methods, lab technology and radiography
disease, health science and nursing

Access to Document

https://doi.org/10.1016/j.plabm.2017.11.002

Cite this

@article{39cec1f0b9824081b638d2a6312fe9f2,

title = "Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis",

abstract = "Objectives Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1–2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration. Design and methods Fifty-five stool samples were analyzed by the IBDoc {\textregistered} Calprotectin Home Testing kit and the B{\"U}HLMANN fCAL {\textregistered} turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated. Results We found a strong correlation coefficient of 0.887 between FC measured on IBDoc{\textregistered} and the laboratory assay B{\"U}HLMANN fCAL {\textregistered} turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3–5.5% (B{\"U}HLMANN fCAL {\textregistered} turbo) and in the range of 4.8–26.6% (IBDoc {\textregistered}). Conclusions This study suggests that IBDoc{\textregistered} is a suitable alternative for the assessment of disease activity in IBD patients.",

keywords = "clinical assessment methods, lab technology and radiography, disease, health science and nursing",

author = "Julie Hejl and Klaus Theede and Brian M{\o}llgren and Madsen, {Kirsten Vikkels{\o}} and Ashraf Heidari and {{\'a} Steig}, Anna and Mogens Fenger",

note = "Publisher Copyright: {\textcopyright} 2017 The Authors",

year = "2018",

month = mar,

doi = "https://doi.org/10.1016/j.plabm.2017.11.002",

language = "English",

volume = "10",

pages = "10--14",

journal = "Practical Laboratory Medicine",

issn = "2352-5517",

publisher = "Elsevier",

}

TY - JOUR

T1 - Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

AU - Hejl, Julie

AU - Theede, Klaus

AU - Møllgren, Brian

AU - Madsen, Kirsten Vikkelsø

AU - Heidari, Ashraf

AU - á Steig, Anna

AU - Fenger, Mogens

PY - 2018/3

Y1 - 2018/3

N2 - Objectives Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1–2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration. Design and methods Fifty-five stool samples were analyzed by the IBDoc ® Calprotectin Home Testing kit and the BÜHLMANN fCAL ® turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated. Results We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL ® turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3–5.5% (BÜHLMANN fCAL ® turbo) and in the range of 4.8–26.6% (IBDoc ®). Conclusions This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients.

AB - Objectives Fecal calprotectin (FC) is widely used to monitor the activity of inflammatory bowel disease (IBD) and to tailor medical treatment to disease activity. Laboratory testing of fecal samples may have a turnaround time of 1–2 weeks, whereas FC home testing allows results within hours and thus enables a rapid response to clinical deterioration. Design and methods Fifty-five stool samples were analyzed by the IBDoc ® Calprotectin Home Testing kit and the BÜHLMANN fCAL ® turbo assay on a Roche Cobas 6000 c501. The correlation between the assays was assessed using Spearman's Rho correlation coefficient and the intermediate imprecision of both assays was calculated. Results We found a strong correlation coefficient of 0.887 between FC measured on IBDoc® and the laboratory assay BÜHLMANN fCAL ® turbo. The coefficients of variation (CVs) at three different FC levels were in the range 2.3–5.5% (BÜHLMANN fCAL ® turbo) and in the range of 4.8–26.6% (IBDoc ®). Conclusions This study suggests that IBDoc® is a suitable alternative for the assessment of disease activity in IBD patients.

KW - clinical assessment methods, lab technology and radiography

KW - disease, health science and nursing

UR - http://www.scopus.com/inward/record.url?scp=85037116596&partnerID=8YFLogxK

U2 - https://doi.org/10.1016/j.plabm.2017.11.002

DO - https://doi.org/10.1016/j.plabm.2017.11.002

M3 - Journal article

SN - 2352-5517

VL - 10

SP - 10

EP - 14

JO - Practical Laboratory Medicine

JF - Practical Laboratory Medicine

ER -

Point of care testing of fecal calprotectin as a substitute for routine laboratory analysis

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this